About: MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Sector: Healthcare
Industry: Biotechnology
Latest price: $52.48 (-4.58%)
MBX NASDAQ MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. Common Stock share price
Atividade de preço de MBX
Último preço
$ 52,480
Variação (24h)
-2,52 USD (4,58%)
Volume
424.98K
Volume (média 4 sem.)
-
Abertura
$ 56,21
Variação do dia
$ 51,73 - $ 57,00
Fechamento anterior
$ 55,00
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
MBX price performance
Atrasado
04 Nov, 9:00 pm GMT+0
MBX details
quote.marketSignals